xxGroundZeroxx Posted - 2 days ago

$BCLI keep a eye on this one it’s been in steady uptrend $IONS $BIIB

johnnygogogo Posted - 2 days ago

$IONS for @skeezbag

buffalosoldiertwo Posted - 2 days ago

$IONS $BIIB Starting to look more and more like Spinraza was just shit dumb luck.

DonCorleone77 Posted - 2 days ago

$BIIB $IONS Biogen, Ionis terminate development of BIIB105 based on data from ALSpire study Biogen (BIIB) and Ionis Pharmaceuticals (IONS) announced the decision to terminate development of BIIB105 an investigational antisense oligonucleotide, ASO, for amyotrophic lateral sclerosis, ALS, based on topline results from the Phase 1/2 ALSpire study. BIIB105 was designed to reduce expression of ataxin-2 protein and demonstrated statistically significant cerebrospinal fluid ATXN2 protein reductions in the study. However, over the 6-month placebo-controlled period, treatment with BIIB105 did not result in a reduction in levels of plasma neurofilament light chain, a marker of neurodegeneration and neuronal damage. Additionally, BIIB105 did not demonstrate an impact on clinical outcome measures of function, breathing, and strength. During the 6-month placebo-controlled portion of the study, the most common adverse events in BIIB105 treated participants were procedural pain, headache and fall. AEs leading to study discontinuation were higher in the BIIB105 group compared with the placebo group.

Stock_Titan Posted - 2 days ago

$IONS $BIIB Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis https://www.stocktitan.net/news/IONS/ionis-and-biogen-announce-topline-phase-1-2-study-results-of-mto0ocbc51tz.html

DonCorleone77 Posted - 2 days ago

$IONS Ionis Pharmaceuticals' ION582 shows improvements in Angelman syndrome Ionis Pharmaceuticals announced positive topline data from the HALOS Phase 1/2a open-label study of ION582 in Angelman syndrome. ION582 was safe and well tolerated in the study and showed encouraging and consistent benefits in individuals living with Angelman syndrome, with the most robust improvements observed in key areas of functioning including cognition, communication and motor function. At six months, approximately 65% of patients achieved an improvement in cognition on the Bayley-4 and showed improvements in Bayley-4 measures of fine and gross motor skills. ION582 was safe and well tolerated at all dose levels. Ionis will independently advance ION582 as part of Ionis' portfolio of potentially transformational medicines for serious neurological diseases. Ionis plans to review the ION582 Phase 1/2a results with regulatory authorities to align on the design of the pivotal program. Biogen has elected not to exercise its option to license ION582.

Stock_Titan Posted - 2 days ago

$IONS Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome https://www.stocktitan.net/news/IONS/ionis-announces-positive-topline-results-from-phase-1-2a-trial-of-y3j0s1zyqos4.html

Bankpas Posted - 1 week ago

$IONS 🙈🙈🙈was 50 and now not even 40 anymore!!! Though the company is progressing well!

briefingcom Posted - 1 week ago

$IONS: Ionis Pharma beats by $0.05, misses on revs; reaffirms FY24 revs guidance https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240507070808IONS&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

Estimize Posted - 1 week ago

$IONS misses the Estimize EPS Consensus by 31c and the Estimize Revenue Consensus by $16.89M. Reports FQ1 earnings of -98c EPS and $119... http://www.estimize.com/ions/fq1-2024?utm_content=beat_or_miss&utm_medium=tweet&utm_source=stocktwits

DonCorleone77 Posted - 1 week ago

$IONS Ionis Pharmaceuticals reports Q1 EPS (98c), consensus ($1.05) Reports Q1 revenue $119M, consensus $135.93M. Cash and short-term investments of $2.2B as of March 31, enable continued investments to drive increasing value, including supporting our planned upcoming launches. "Ionis is off to a great start in 2024, as we continue to execute on our vision to bring better futures to people with serious diseases. The WAINUA launch for hereditary ATTR polyneuropathy is progressing well with AstraZeneca. And we are one step closer to our first independent launch with our NDA submission for olezarsen, which is supported by robust data positioning olezarsen to make a profound difference for people with FCS," said Brett P. Monia, CEO of Ionis. "We look forward to presenting positive Phase 3 donidalorsen data, along with data from our open-label extension and 'switch' studies in patients with HAE at EAACI later this month, setting the stage for Ionis' second independent launch. Additionally, we have multiple upcoming data readouts from our mid-stage programs that, if positive, could advance into Phase 3 development, further strengthening our ability to deliver a steady cadence of potentially transformational medicines for years to come."

epsguid Posted - 1 week ago

$IONS reported a loss of $0.98, consensus was ($1.10) via @eWhispers #epsbeat http://eps.sh/d/ions

Stock_Titan Posted - 1 week ago

$IONS Ionis reports first quarter 2024 financial results https://www.stocktitan.net/news/IONS/ionis-reports-first-quarter-2024-financial-m3jpz2gowymo.html

CaptainAmrica Posted - 2 weeks ago

$IONS I remember many many years ago reading a magazine called Worth and interview with great Peter Lynch...He was asked to pick one stock for the next 50years....Of all the companies, he said Isis Pharma....Well its been now 40 years and the stock is sitting doing absolute nothing.....Overpromise and under performance on this once promising company....

Coleperris55 Posted - 2 weeks ago

$IONS VWAP @ $42.50 on 5 min timeframe. RSI @ 19.03 (OVERSOLD) Current Price @ $41.97 Swing = $0.53 or 1.25%

Quantumup Posted - 2 weeks ago

H.C. Wainwright initiated $SGMT Buy/$32: Says, FiC MoA, QD oral pill denifanstat has the pot to emerge as a backbone Tx for MASH; 52wk biopsy data demonstrated highly stat sig reductions in NASH resolution (> $MDGL resmetirom) and fibrosis improvement: $IVA $VKTX ETNB AKRO ALGS $IONS LLY

sickeconomics Posted - 04/26/24

Tomorrow's Big Pharma, today? $IONS $VRTX $PFE $JNJ $LLY https://www.sickeconomics.com/2024/04/22/ionis-pharmaceuticals-the-little-big-pharma/

Stock_Titan Posted - 04/25/24

$IONS Ionis Publishes 2023 Corporate Responsibility Report https://www.stocktitan.net/news/IONS/ionis-publishes-2023-corporate-responsibility-bet2hwzr8oqg.html

fda_tracker Posted - 04/24/24

$IONS Phase 2 trial w/est Apr completion date NCT03815825: https://www.clinicaltrials.gov/study/NCT03815825 Trial Tracker: https://www.fdatracker.com/trial-tracker/

fda_tracker Posted - 04/23/24

$IONS Phase 2 trial w/est Apr completion date NCT04014335: https://www.clinicaltrials.gov/study/NCT04014335 Trial Tracker: https://www.fdatracker.com/trial-tracker/

Stock_Titan Posted - 04/23/24

$IONS Ionis to hold first quarter 2024 financial results webcast https://www.stocktitan.net/news/IONS/ionis-to-hold-first-quarter-2024-financial-results-ugaqgmb5na6u.html

STOCKPICKERTRADER Posted - 1 month ago

$PFE loads of other over cooked biotech/pharma companies out there if you look around, but feeling a bit overdone and seeing some potential bottoming in number of them. Few more below to add to prior lists - still like Pfizer as one of the top better/bigger plays. $IONS $NTLA $ILMN

insiderbuyingselling Posted - 1 month ago

$IONS new insider selling: 905 shares. http://insiderbuyingselling.com/?t=IONS

buffalosoldiertwo Posted - 1 month ago

$IONS always a good sign when the CBO banks 6,000 shares. https://ir.ionispharma.com/node/31136/html

Quantumup Posted - 1 month ago

Wolfe Research $IONS Upgrading to Outperform on Catalysts (HELIOS-B & more)/Revenue Potential (SHTG & more) Sees HELIOS-B readout as risky cat, but expects favorable R/R4 $IONS movement (more so than $ALNY). Now models $2.1B peak rev for olezarsen. Pelacarsen not in model=pot upside. $vrtx

Bankpas Posted - 1 month ago

$IONS Oppenheimer Raises Ionis Pharmaceuticals' Price Target to $75 From $72, Maintains Outperform Rating

Bankpas Posted - 1 month ago

$IONS

Bankpas Posted - 1 month ago

$IONS news keeps getting better and the stock keeps declining…we should be at 60 dollar by now!

Theflash88 Posted - 1 month ago

$IONS Expect a pop.

OpenOutcrier Posted - 1 month ago

$IONS (+2.6% pre) Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome - SI https://ooc.bz/l/29707